Accessibility Menu
Elutia logo

Elutia(NASDAQ) ELUT

Market Cap$38.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-94%
5 Year-89%
1 Year-57%
1 Month-8%
$0.89
+1.72%
+0.01Today
Elutia last closing stock price
MetricPriceDate
Last closeUSD 0.872026-08-05
Elutia stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.91%USD 0.882026-07-29
1 month-8%USD 0.952026-07-06
3 month-12.7%USD 1.002026-05-07
Year to date+25.88%USD 0.692025-12-31
1 year-57.25%USD 2.042025-08-05
3 year-54.11%USD 1.902023-08-04
5 year-89.26%USD 8.122021-08-06
Since inception-93.99%USD 14.502020-10-08

Elutia Financials at a Glance

Market Cap

$38.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$15.97M

Net Income (TTM)

$49.84M

EPS (TTM)

-$0.76

P/E Ratio

-1.15

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.89

Volume

2,293.942

Open

$0.86

Previous Close

$0.87

Daily Range

$0.86 - $0.88

52-Week Range

$0.50 - $2.50

Estimated Earnings Date

Aug 13, 2026

ELUT News

Foolcom-Featured.png

Elutia Posts Narrower Loss in Fiscal Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Elutia

Elutia makes products that help protect implanted medical devices and support tissue repair. Its main offerings reduce infection risk for patients with pacemakers or after surgery. Hospitals use these products to improve patient recovery and lower complications.

Gadgets, Grafts, and Good Health: What Elutia Sells

  • Device Protection (53.6% of sales): Bioenvelopes for pacemakers and defibrillators, with antibiotics to lower infection risk.
  • Women’s Health (37.7%): Human tissue-based materials for breast reconstruction, hernia repair, and sports injuries.
  • Cardiovascular (8.6%): Patches and repair materials for heart and blood vessel surgeries, including products for infants.

Growth Spurts and Strategic Moves

  • Launched EluPro, a new antibiotic device protection product, in January 2025 after FDA clearance in June 2024.
  • Sold Orthobiologics business in November 2023 for $14.6 million upfront, with possible future payments.
  • Formed partnerships with Boston Scientific (Device Protection) and Tiger Aesthetics Medical (Women’s Health) to expand sales reach.
  • Leased new production and lab space in Gaithersburg, Maryland, in 2025 to support in-house manufacturing.
  • Shifted cardiovascular product sales from LeMaitre Vascular to direct sales in May 2025.

Why Elutia Catches the Eye

Elutia focuses on combining biologic materials with local drug delivery to improve patient outcomes. Its products are distributed mainly in the U.S. through direct sales, agents, and partners. The company holds patents for its tissue repair and infection-prevention technologies.

Five Things You Need to Know

  • Q3 2025 revenue was $3 million, down 43.9% from Q3 2024.
  • Device Protection sales rose 33.2% year-over-year in Q2 2025.
  • Net loss improved to $-5 million in Q3 2025, up 49.1% year-over-year.
  • Gross margin reached 48.8% in Q2 2025, up from 44.5% in Q2 2024.

Bottom Line

Elutia has shifted its focus to core device protection and tissue repair markets. The company faces ongoing financial and legal challenges but continues to adapt its product mix and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

26

CEO

Charles Randal Mills, PhD

Website

www.elutia.com

Headquarters

Gaithersburg, MD 20878, US

ELUT Financials

Key Financial Metrics (TTM)

Gross Margin

54.02%

Operating Margin

-159.43%

Net Income Margin

312.09%

Return on Equity

-560.64%

Return on Capital

-47.40%

Return on Assets

90.28%

Earnings Yield

-86.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$38.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

44.21M

Volume

2.29K

Avg. Volume

104.29K

Financials (TTM)

Gross Profit

$8.63M

Operating Income

-$25.46M

EBITDA

-$25.04M

Operating Cash Flow

-$43.76M

Capital Expenditure

-$2.06M

Free Cash Flow

-$45.82M

Cash & ST Invst.

$28.49M

Total Debt

$4.22M

Elutia Performance Analysis

Elutia annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 23,849,000-49.7%
20232023-12-31USD 24,745,0003.8%
20242024-12-31USD 14,467,000-41.5%
20252025-12-31USD 12,293,000-15.0%
Elutia sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-303.9%
Q32025-09-30-46.9%
Q42025-12-31-1.6%
Q12026-03-31-4.8%
Elutia annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.380.0%
20232023-12-31USD -2.401.1%
20242024-12-31USD -1.86-22.8%
20252025-12-31USD -0.79-57.4%
Elutia sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-23.8%
Q32025-09-3026.9%
Q42025-12-31878.9%
Q12026-03-31-111.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.11M

-48.4%

Gross Profit

$1.80M

-26.7%

Gross Margin

57.87%

N/A

Market Cap

$38.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.48M

N/A

Employees

26

N/A

Net Income

-$7.47M

-89.9%

EBITDA

-$7.60M

-285.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$28.49M

+64.1%

Total Debt

$4.22M

-83.1%

Accounts Receivable

$2.07M

-27.7%

Inventory

$2.66M

-38.0%

Long Term Debt

$3.70M

-83.3%

Short Term Debt

$1.05M

-64.3%

Return on Assets

90.28%

N/A

Return on Invested Capital

-80.88%

N/A

Free Cash Flow

-$8.29M

+9.5%

Operating Cash Flow

-$7.83M

+11.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANVSAnnovis Bio, Inc.
$1.83-2.40%
LTRNLantern Pharma Inc.
$2.81+0.36%
RNXTRenovoRx, Inc.
$1.14+7.55%
PYPDPolyPid Ltd.
$4.71+2.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$109.35+0.01%
NVDANvidia
$219.23+0.00%
SOUNSoundHound AI
$7.17+0.11%
CLROClearOne
$9.07+1.46%

Questions About ELUT

What is the current price of Elutia?

Elutia is trading at $0.88 per share.

What is the 52-week range for Elutia?

Over the past 52 weeks, Elutia has traded between $0.50 and $2.50.

How much debt does Elutia have?

As of the most recent reporting period, Elutia reported total debt of $11.59M.

How much cash does Elutia have on hand?

Elutia reported $28.49M in cash and cash equivalents in its most recent financial results.

What is Elutia’s dividend yield?

Elutia does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services